Streetbeat News

BCDA

BioCardia, Inc.

https://www.biocardia.com

Industry

Biotechnology

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Open

1.98

Mkt cap

8.5M

Volume

77K

High

2.01

P/E Ratio

-0.38

52-wk high

11.55

Low

1.84

Div yield

N/A

52-wk low

1.84

BioCardia (NASDAQ:BCDA) reported Q3 2023 GAAP EPS of $(0.12), meeting analyst consensus. This is a 29.41% increase over losses from the same period last year. The company's quarterly sales of $357.00K beat the analyst consensus estimate of $20.00K by 1.69K percent, marking a 68.40% increase over sales from the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 08, 2023 | 10:20 pm

BioCardia (NASDAQ:BCDA) is set to release its quarterly earnings report on November 8, 2023. Analysts estimate an earnings per share (EPS) of $-0.12. The company's past performance shows a trend of missing EPS estimates, which has led to share price drops. The company's shares are currently trading at $0.405 and have seen a 78.11% decrease over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 8:02 pm

BioCardia has filed for a mixed shelf offering of up to $50 million, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 1:31 pm

Over the past 3 months, 4 analysts have published their opinion on BioCardia (NASDAQ:BCDA) stock, all of them being bullish. The average price target is $6.5, implying significant upside from the current price of $0.3976. However, this average has decreased by 27.78% from the previous average price target of $9.00.

Portfolio Pulse from Benzinga Insights

October 11, 2023 | 7:00 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on BioCardia (NASDAQ:BCDA) and maintained a $4 price target.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 4:35 pm

BioCardia, Inc. (NASDAQ:BCDA) has completed enrollment for its CardiAMP Heart Failure Trial and is initiating discussions with the FDA for a second pivotal study protocol. The aim of the second study is to gain FDA marketing approval.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 10:02 am

Healthcare stocks showed significant movement in Friday's pre-market session. RVL Pharmaceuticals, Vaccinex, T2 Biosystems, Akso Health Group, Exagen, and Bone Biologics saw gains, while Freeline Therapeutics, Nanobiotix, Longeveron, Vivos Therapeutics, BioCardia, and Koninklijke Philips experienced losses.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 1:06 pm

During Friday's session, 169 companies set new 52-week lows. Among them, Bristol-Myers Squibb was the largest firm by market cap to set a new 52-week low, while Blue Star Foods was the smallest. PTC Therapeutics' stock fell the most, trading down 31.29% to reach a new 52-week low. Meanwhile, Prelude Therapeutics' stock bounced back the most, rising 0.0% after reaching its new 52-week low.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 3:52 pm

On Wednesday, 179 companies reached new 52-week lows. Pfizer (NYSE:PFE) was the largest company to set a new 52-week low, while Gaucho Group Holdings (NASDAQ:VINO) was the smallest. EZGO Technologies (NASDAQ:EZGO)'s stock fell the most, dropping 78.43% to reach a new 52-week low. Protara Therapeutics (NASDAQ:TARA)'s stock made the biggest reversal, trading up 0.0% shortly after dropping to a new 52-week low.

Portfolio Pulse from Benzinga Insights

September 06, 2023 | 6:43 pm

HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on BioCardia (NASDAQ:BCDA) but has lowered the price target from $9 to $4.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 2:50 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.